Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

European Journal of Clinical Pharmacology

Volumn 64, Issue 9, 2008, Pages 871-876

  Bohanec Grabar, Petra ^a   Rozman, Blaž ^b   Tomšič, Matija ^b   Šuput, Daša ^b   Logar, Dušan ^b   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cytochromes P450; Leflunomide toxicity; Polymorphism; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; CELECOXIB; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETODOLAC; IBUPROFEN; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHMA; COXITIS; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; DIARRHEA; DRUG ACTIVATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FURUNCULOSIS; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAIL DISEASE; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; TASTE DISORDER; TREMOR; URINARY TRACT INFECTION; VAGINITIS; VERTIGO; VOMITING; WEIGHT REDUCTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOCHROME P-450 CYP1A2; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NAUSEA; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, GENETIC; PRURITUS; VOMITING;

EID: 50849104253     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0498-2     Document Type: Article

References (26)

1. V Mladenovic Z Domljan B Rozman I Jajic D Mihajlovic J Dordevic 1995 Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study Arthritis Rheum 38 1595 1603
2. AS Kalgutkar HT Nguyen AD Vaz A Doan DK Dalvie DG McLeod 2003 In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos 31 1240 1250
3. C Sachse J Brockmoller S Bauer I Roots 1999 Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine Br J Clin Pharmacol 47 445 449
4. SM De Morais GR Wilkinson J Blaisdell UA Meyer K Nakamura JA Goldstein 1994 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 594 598
5. SM de Morais GR Wilkinson J Blaisdell K Nakamura UA Meyer JA Goldstein 1994 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 15419 15422
6. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113
7. P He MH Court DJ Greenblatt LL Von Moltke 2005 Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo Clin Pharmacol Ther 77 373 387
8. J Chonlahan MA Halloran A Hammonds 2006 Leflunomide and warfarin interaction: case report and review of the literature Pharmacotherapy 26 868 871
9. V Lim I Pande 2002 Leflunomide can potentiate the anticoagulant effect of warfarin BMJ 325 1333
10. C Sevilla-Mantilla L Ortega JA Agundez B Fernandez-Gutierrez JM Ladero M Diaz-Rubio 2004 Leflunomide-induced acute hepatitis Dig Liver Dis 36 82 84
11. AE Rettie LC Wienkers FJ Gonzalez WF Trager KR Korzekwa 1994 Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 Pharmacogenetics 4 39 42
12. TH Sullivan-Klose BI Ghanayem DA Bell ZY Zhang LS Kaminsky GM Shenfield 1996 The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism Pharmacogenetics 6 341 349
13. G Kunkel G Cannon 2006 Leflunomide in the treatment of rheumatoid arthritis Expert Rev Clin Immunol 2 17 31
14. D Aletaha T Stamm T Kapral G Eberl J Grisar KP Machold 2003 Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study Ann Rheum Dis 62 944 951
15. EN van Roon TL Jansen MA van de Laar M Janssen JP Yska R Keuper 2005 Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis Ann Rheum Dis 64 569 574
16. V Chan BG Charles SE Tett 2005 Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis Br J Clin Pharmacol 60 257 264
17. EK Li LS Tam B Tomlinson 2004 Leflunomide in the treatment of rheumatoid arthritis Clin Ther 26 447 459
18. B Rozman 2002 Clinical pharmacokinetics of leflunomide Clin Pharmacokinet 41 421 430
19. JS Smolen JR Kalden DL Scott B Rozman TK Kvien A Larsen 1999 Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group Lancet 353 259 266
20. Tiilikainen A, Fischer G, Grubic Z, Gyodi E, Ivaskova E, Jungerman M et al (1997) Anthropological features of the East European region. In: Charron D (ed) HLA: genetic diversity of HLA functional and medical implication. Proceedings of the 12th International Histocompatibility Workshop and Conference, EDK, Medical and Scientific International Publisher, Paris
21. Vidan-Jeras B, Jurca B, Dolzan V, Jeras M, Breskvar K, Bohinjec M (1998) Caucasian Slovenian normal. In: Gjertson D, Terasaki P (eds) HLA 1998, American society for histocompatibility and immunogenetics, Lenexa
22. D Herman V Dolzan K Breskvar 2003 Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population Zdrav Vestn 72 347 351
23. EN van Roon JP Yska J Raemaekers TL Jansen M van Wanrooy JR Brouwers 2004 A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy J Pharm Biomed Anal 36 17 22
24. XM Han DS Ouyang XP Chen Y Shu CH Jiang ZR Tan 2002 Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2 Br J Clin Pharmacol 54 540 543
25. KL Rost I Roots 1994 Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test Clin Pharmacol Ther 55 402 411
26. R Ghotbi M Christensen HK Roh M Ingelman-Sundberg E Aklillu L Bertilsson 2007 Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans Eur J Clin Pharmacol 63 537 546